Juncture Wealth Strategies LLC acquired a new position in shares of GlaxoSmithKline plc (NYSE:GSK) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 5,800 shares of the pharmaceutical company’s stock, valued at approximately $232,000.

Several other institutional investors and hedge funds have also modified their holdings of GSK. Comerica Securities Inc. grew its position in shares of GlaxoSmithKline by 2.6% during the fourth quarter. Comerica Securities Inc. now owns 12,984 shares of the pharmaceutical company’s stock worth $502,000 after purchasing an additional 326 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of GlaxoSmithKline by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,769,859 shares of the pharmaceutical company’s stock worth $67,626,000 after purchasing an additional 88,148 shares in the last quarter. Geode Capital Management LLC grew its position in shares of GlaxoSmithKline by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 424,397 shares of the pharmaceutical company’s stock worth $16,216,000 after purchasing an additional 48,476 shares in the last quarter. Cetera Advisors LLC grew its position in shares of GlaxoSmithKline by 23.5% during the fourth quarter. Cetera Advisors LLC now owns 16,833 shares of the pharmaceutical company’s stock worth $643,000 after purchasing an additional 3,205 shares in the last quarter. Finally, Millennium Management LLC grew its position in shares of GlaxoSmithKline by 612.0% during the fourth quarter. Millennium Management LLC now owns 365,325 shares of the pharmaceutical company’s stock worth $13,959,000 after purchasing an additional 314,016 shares in the last quarter. 11.26% of the stock is owned by institutional investors and hedge funds.

Several analysts recently issued reports on the company. Morgan Stanley assumed coverage on in a research report on Monday, June 17th. They set an “equal weight” rating and a GBX 215 ($2.81) target price for the company. Zacks Investment Research upgraded Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. Finally, Cowen reiterated a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $42.66.

In other news, Director Plc Glaxosmithkline purchased 385,714 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was bought at an average cost of $14.00 per share, with a total value of $5,399,996.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

Shares of GlaxoSmithKline stock opened at $41.91 on Friday. The company’s 50 day moving average price is $40.59. GlaxoSmithKline plc has a 12 month low of $36.41 and a 12 month high of $42.20. The company has a market capitalization of $103.96 billion, a price-to-earnings ratio of 13.26, a PEG ratio of 2.12 and a beta of 0.74. The company has a debt-to-equity ratio of 7.86, a quick ratio of 0.48 and a current ratio of 0.71.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.14. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. On average, sell-side analysts predict that GlaxoSmithKline plc will post 2.9 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, July 11th. Investors of record on Friday, May 17th were paid a dividend of $0.4953 per share. This represents a $1.98 dividend on an annualized basis and a yield of 4.73%. The ex-dividend date of this dividend was Thursday, May 16th. GlaxoSmithKline’s payout ratio is presently 58.86%.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Bear Market

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.